Ziconotide intrathecal delivery as treatment for secondary therapeutic failure of motor cortex stimulation after 6 years
Autor: | D. Fischer, François Proust, A. Simon, I. Darie, I. Rohmer-Heitz, J. Voirin |
---|---|
Přispěvatelé: | Laboratoire des sciences de l'ingénieur, de l'informatique et de l'imagerie (ICube), École Nationale du Génie de l'Eau et de l'Environnement de Strasbourg (ENGEES)-Université de Strasbourg (UNISTRA)-Institut National des Sciences Appliquées - Strasbourg (INSA Strasbourg), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National de Recherche en Informatique et en Automatique (Inria)-Les Hôpitaux Universitaires de Strasbourg (HUS)-Centre National de la Recherche Scientifique (CNRS)-Matériaux et Nanosciences Grand-Est (MNGE), Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Réseau nanophotonique et optique, Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS) |
Jazyk: | angličtina |
Rok vydání: | 2016 |
Předmět: |
Male
medicine.medical_specialty Stimulation omega-Conotoxins 03 medical and health sciences 0302 clinical medicine medicine Humans Pain Management 030212 general & internal medicine Pain Measurement Salvage Therapy Ziconotide business.industry Motor Cortex Postoperative complication Motor cortex stimulation Surgery Catheter Anesthesia [INFO.INFO-TI]Computer Science [cs]/Image Processing [eess.IV] Neuropathic pain Quality of Life Morphine Neuralgia Anxiety Neurology (clinical) medicine.symptom business 030217 neurology & neurosurgery Follow-Up Studies medicine.drug |
Zdroj: | Neurochirurgie Neurochirurgie, 2016, 62 (5), ⟨10.1016/j.neuchi.2016.06.007⟩ |
ISSN: | 0028-3770 1773-0619 |
DOI: | 10.1016/j.neuchi.2016.06.007⟩ |
Popis: | Introduction Motor cortex stimulation is a well-known treatment modality for refractory neuropathic pain. Nevertheless, some cases of therapeutic failure have been described but alternative therapies for these cases are rarely reported. Case report The patient presented with neuropathic pain in his right arm due to a cervical syrinx which was surgically treated by a shunt in 2003 with no clinical improvement. As alternative therapy, after an evaluation by repetitive magnetic transcranial stimulation with significant benefit, motor cortex stimulation was successfully implanted in 2004. In 2010, a similar pain occurred in the same territory. Local mean pain visual analogical scale (VAS) increased to 82/100. A newer generation stimulation device was then implanted and, within a period of 8 months, different stimulation parameter settings were tested, without any pain relief. An intrathecal drug delivery pump was then implanted in 2011, and the upper extremity catheter was located at the cervicothoracic junction. There was no postoperative complication. A bitherapy was initiated at a daily dosage of 0.2 mg morphine and 1.3 μg ziconotide, not modified since August 2013. At 43 months follow-up, mean VAS was 21/100 with improvement of daily life and spare-time activities, anxiety and depression, quality of life (as measured by the SF-36 survey and EQ5D-3L questionnaire). Discussion Refractory neuropathic pain treated by motor cortex stimulation may be considered in palliative situations, and secondary therapeutic failure offers only a few perspectives. Intrathecal ziconotide, indicated as a first-line drug in non-cancer pain, could be proposed in such cases. Conclusion Intrathecal drug delivery including ziconotide in refractory neuropathic pain represents a reasonable option with a good clinical tolerance. |
Databáze: | OpenAIRE |
Externí odkaz: |